Skip to main content
. 2016 May 17;43(1):160–170. doi: 10.1093/schbul/sbw061

Table 1.

Demographic Characteristics of the Participants (n = 159)

Controls (n = 49) Siblings (n = 55) Patients (n = 55)
Time Point 0 1 0 1 0 1
Scan interval (d) 1222±198 1177±101 1196±121
Age at scan (y) 31.0±11.0 34.4±10.9 30.9±8.5 34.1±8.5 28.7±6.3 32.0±6.2
Sex, male (%) 19 (39%) 29 (53%) 40 (73%)
Handedness 83.2 78.0 72.2
Level of education 5.4±2.0 5.4±2.1 4.5±1.9
Age of onset (y) 21.8±6.3
Illness duration (y) 5.7±3.5 10.3±4.0
AP medication 6693±6254a 5335±5715b
Diagnosis
 Schizophrenia 33
 Schizoaffective disorder 16
 Psychotic disorder NOS 6
 Major depressive disorderc 11 15
Substance use
 Cannabis 4.8±32.0d 7.1±49.1d 36.5±105.2d
 Other drugs 0.0 0.0 15.2±57.0d
 Alcohol 6.3±10.8e 6.0±5.4e 4.9±7.6e
PANSS scores
 Positive symptoms 7.3±1.2 7.4±0.8 7.4±0.9 7.4±0.7 9.6±3.7 11.6±5.7
 Negative symptoms 8.2±1.2 8.0±0.2 8.2±1.3 8.0±0.3 11.4±5.2 11.1±4.2
 Disorganization 10.3±1.5 10.1±0.3 10.3±0.6 10.1±0.4 11.7±2.6 11.8±2.5
 Excitement 8.4±1.3 8.3±0.5 8.5±1.2 8.3±0.6 9.4±1.9 9.7±2.5
 Emotional distress 9.3±2.1 9.4±1.7 9.7±2.2 9.7±2.2 12.9±5.2 14.1±5.0
Remission (percentage) 61% 62%

Note: Means ± SDs are reported. AP, antipsychotic; NOS, not otherwise specified; PANSS, Positive and Negative Syndrome Scale.

aCumulative exposure (in haloperidol equivalents), lifetime until baseline assessment.

bExposure (in haloperidol equivalents) over last 3 y.

cHistory of major depressive disorder, no current episodes at baseline or in last 3 y.

dMean number of times; last 12 mo.

eWeekly consumptions last 12 mo.